Center for Biologics Evaluation and Research CBER Vision:2004 - a strategic plan
This article was originally published in Clinica
Executive Summary
The FDA's Center for Biologics Evaluation & Research will unveil "CBER Vision:2004", its strategic plan for the next decade, at a vaccines advisory committee meeting this week. CBER director Kathy Zoon is excited about the plan for the agency which regulates a good amount of blood-related technology. Manufacturers of blood washers, warmers and freezers and other equipment used in blood banks; in vitro diagnostics manufacturers whose products are used in screening for manufacturing or transfusion; sources of HIV tests and their associated hardware will all be affected.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.